Ftse Mib
36.525,86
-0,53%
DAX
21.418,50
-0,43%
S&P 500
6.037,88
0,72%
NASDAQ
19.654,02
1,35%
Bitcoin
97.768,98
-0,09%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kymera Therapeutics Inc (KYMR) Kymera Therapeutics Inc (KYMR) Notizie

KYMR

Kymera Therapeutics (KYMR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KYMR
DataOraFonteTitoloSimboloCompagnia
30/01/202513:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming February Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
14/01/202522:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
14/01/202513:00GlobeNewswire Inc.Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsNASDAQ:KYMRKymera Therapeutics Inc
13/01/202513:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
07/01/202513:00GlobeNewswire Inc.Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14NASDAQ:KYMRKymera Therapeutics Inc
26/11/202413:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming December Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
05/11/202413:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
31/10/202413:13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:KYMRKymera Therapeutics Inc
31/10/202412:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KYMRKymera Therapeutics Inc
31/10/202412:30GlobeNewswire Inc.Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
24/10/202413:00GlobeNewswire Inc.Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory DiseasesNASDAQ:KYMRKymera Therapeutics Inc
23/10/202413:15GlobeNewswire Inc.Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31NASDAQ:KYMRKymera Therapeutics Inc
23/10/202413:00GlobeNewswire Inc.Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 SymposiumNASDAQ:KYMRKymera Therapeutics Inc
09/10/202413:00GlobeNewswire Inc.Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 DegraderNASDAQ:KYMRKymera Therapeutics Inc
25/09/202413:00GlobeNewswire Inc.Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV CongressNASDAQ:KYMRKymera Therapeutics Inc
28/08/202413:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming September Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
21/08/202417:15GlobeNewswire Inc.Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:KYMRKymera Therapeutics Inc
20/08/202422:31Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
20/08/202404:45GlobeNewswire Inc.Kymera Therapeutics Announces Pricing of $225 Million Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
19/08/202422:01GlobeNewswire Inc.Kymera Therapeutics Announces Proposed Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
07/08/202413:00GlobeNewswire Inc.Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
31/07/202413:00GlobeNewswire Inc.Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7NASDAQ:KYMRKymera Therapeutics Inc
16/07/202422:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
09/07/202413:00GlobeNewswire Inc.Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation DayNASDAQ:KYMRKymera Therapeutics Inc
09/07/202412:54IH Market NewsBP Slashes Profit Forecast by $700 Million; Morgan Stanley Predicts S&P 500 10% Drop, and More NewsNASDAQ:KYMRKymera Therapeutics Inc
08/07/202422:05GlobeNewswire Inc.Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and EfficacyNASDAQ:KYMRKymera Therapeutics Inc
14/06/202413:00GlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
01/06/202414:00GlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
29/05/202413:00GlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
23/05/202423:00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KYMR

La tua Cronologia

LSE
GSK
Gsk
NASDAQ
CBWBX
Ci Canadian Dividend Cor...
TSXV
GRG
Golden Arrow Resources
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci